The single cell encapsulation set-up, Dolomite uEncapsulator, is used to focus on vaccine delivery by incorporating self-amplifying RNA with lipids, which allows the RNA to determine cellular uptake and protein expression.
A spokesperson for Dolomite told us, “The liposomal formulations consist of a cationic lipid (usually either DDA or DOTAP), and a phospholipid such as DOPE and cholesterol.”
By incorporating a cationic lipid in the liposome, the formulation is able to “efficiently deliver RNA vaccines” that are more biocompatible compared with other delivery vehicles, the spokesperson further explained.
To create the formulation, the Dolomite uEncapsulator produces liposomes in large batches and then mixes the liposomes with RNA.
According to Dolomite, the set-up can vary flow rates of the mixing stream and temperature, which enables precise size control of the liposomes.
The set-up is currently used at Imperial College London for the development of RNA vaccines in liposomal formulations, targeting diseases such as HIV, influenza, rabies and chlamydia.
